Healthcare Services

cfDNA testing market analysis (2026–2030)

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Cell Free DNA (cfDNA) Testing Market Grow Between 2026 And 2030?

The cell free dna (cfdna) testing market has demonstrated significant expansion in recent years. This market is expected to increase from $10.84 billion in 2025 to $13.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.8%. Factors contributing to its historical growth include the rising occurrence of cancer diagnostics, the embrace of non-invasive testing methodologies, the expansion of prenatal screening programs, enhancements in sequencing technologies, and the growing clinical recognition of liquid biopsy.

The cell free dna (cfdna) testing market size is expected to undergo significant expansion in the upcoming years. It is projected to grow to $28.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.0%. This growth during the forecast period can be attributed to increasing investments in precision oncology, a rising demand for early cancer detection, the expansion of transplant monitoring applications, the growing adoption of personalized medicine, and the increasing integration of AI-driven genomic analysis. Notable trends within the forecast period include the increasing adoption of liquid biopsy diagnostics, the rising use of NGS-based cfdna analysis, a growing demand for non-invasive prenatal testing, the expansion of oncology monitoring applications, and the enhanced integration of bioinformatics platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

What Key Factors Are Shaping The Cell Free DNA (cfDNA) Testing Market Landscape?

The expanding occurrence of cancer is anticipated to stimulate the growth of the cell-free DNA (cfDNA) testing market in the future. Cancer constitutes a complex set of diseases marked by the uncontrolled multiplication and spread of abnormal cells within the body. These cells have the capacity to invade and damage normal tissue, potentially causing significant harm if not managed. The increasing incidence of cancer is linked to an aging populace, shifts in lifestyle, environmental influences, and advances in detection and diagnostic techniques. cfDNA testing identifies genetic mutations associated with cancer at an early stage, frequently before symptoms manifest, enabling timely intervention that enhances patient outcomes and survival rates by detecting the disease in its initial phases. For example, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, in February 2024, new cancer cases are projected to surpass 35 million in 2050, indicating a 77% rise from the 20 million cases estimated for 2022. Thus, the escalating prevalence of cancer is driving the expansion of the cell-free DNA (cfDNA) testing market.

Which Segments Define The Cell Free DNA (cfDNA) Testing Market Segment Structure?

The cell free dna (cfdna) testing market covered in this report is segmented –

1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA

2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms

3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications

Subsegments:

1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection

2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy

3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening

What Market Trends Are Affecting The Cell Free DNA (cfDNA) Testing Market?

Leading companies active in the cell-free DNA (cfDNA) testing market are concentrating on creating advanced technologies, such as liquid biopsy tests, which offer improved sensitivity, specificity, and efficiency for identifying cancer-related mutations and genetic alterations. Liquid biopsy tests represent diagnostic methods that enable oncologists to assess circulating cell-free DNA released by tumor cells, thereby aiding in the development of personalized, targeted treatment strategies. As an illustration, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences firm, introduced Labcorp Plasma Focus, a new liquid biopsy test tailored for individuals with advanced or metastatic solid tumors. This test evaluates circulating cell-free DNA (cfDNA) released by tumor cells from a routine blood draw, providing a minimally invasive approach with rapid results. It enhances access to precision oncology by identifying clinically actionable biomarkers across several common cancers, including non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.

Who Are The Established Players Within The Cell Free DNA (cfDNA) Testing Market?

Major companies operating in the cell free dna (cfdna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

Get The Full Cell Free DNA (cfDNA) Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

Which Region Has The Greatest Market Share In The Cell Free DNA (cfDNA) Testing Market?

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free dna (cfdna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell Free DNA (cfDNA) Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

Browse Through More Reports Similar to the Global Cell Free DNA (cfDNA) Testing Market 2026, By The Business Research Company

Dna Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-diagnostics-global-market-report

Dna Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Cell Free Dna Isolation And Extraction Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-free-dna-isolation-and-extraction-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795